https://ir.rezolutebio.com/ https://ir.rezolutebio.com/corporate-presentation https://ir.rezolutebio.com/news https://ir.rezolutebio.com/events https://ir.rezolutebio.com/quote-and-chart https://ir.rezolutebio.com/historical-data https://ir.rezolutebio.com/analyst-coverage https://ir.rezolutebio.com/sec-filings https://ir.rezolutebio.com/governance https://ir.rezolutebio.com/governance/governance-documents https://ir.rezolutebio.com/info https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting 2026-03-24T10:37:26-04:00 https://ir.rezolutebio.com/news/detail/372/rezolute-to-participate-in-the-citizens-life-sciences-conference 2026-03-04T07:00:02-05:00 https://ir.rezolutebio.com/news/detail/371/rezolute-reports-second-quarter-fiscal-2026-financial-results-and-provides-business-update 2026-02-12T16:05:04-05:00 https://ir.rezolutebio.com/news/detail/370/rezolute-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026 2026-02-04T07:00:02-05:00 https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism 2026-01-07T15:48:29-05:00 https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism 2025-12-11T07:00:03-05:00 https://ir.rezolutebio.com/news/detail/367/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-11-10T17:30:02-05:00 https://ir.rezolutebio.com/news/detail/366/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update 2025-11-06T16:05:12-05:00 https://ir.rezolutebio.com/news/detail/365/rezolute-to-host-virtual-investor-event-on-ersodetug-development-program 2025-11-05T07:30:30-05:00 https://ir.rezolutebio.com/news/detail/364/rezolute-to-participate-in-upcoming-investor-conferences 2025-10-15T08:00:04-04:00 https://ir.rezolutebio.com/news/detail/363/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-10-09T16:05:09-04:00 https://ir.rezolutebio.com/news/detail/362/rezolute-reports-fourth-quarter-and-full-year-fiscal-2025-financial-results-and-provides-business-update 2025-09-17T16:05:02-04:00 https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism 2025-09-02T07:30:04-04:00 https://ir.rezolutebio.com/news/detail/360/rezolute-to-participate-in-upcoming-investor-conferences 2025-08-27T07:30:07-04:00 https://ir.rezolutebio.com/news/detail/359/rezolute-appoints-seasoned-commercial-executive-sunil-karnawat-as-chief-commercial-officer 2025-08-20T07:30:02-04:00 https://ir.rezolutebio.com/news/detail/358/rezolute-to-participate-in-the-btig-virtual-biotechnology-conference 2025-07-22T07:30:01-04:00 https://ir.rezolutebio.com/news/detail/357/rezolute-announces-presentation-of-participant-baseline-data-from-its-fully-enrolled-phase-3-study-of-ersodetug-in-congenital-hyperinsulinism-at-the-upcoming-annual-meeting-of-the-endocrine-society-endo-2025 2025-07-09T07:30:03-04:00 https://ir.rezolutebio.com/news/detail/356/rezolute-announces-completion-of-enrollment-in-the-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism 2025-05-28T08:00:15-04:00 https://ir.rezolutebio.com/news/detail/355/rezolute-reports-third-quarter-fiscal-2025-financial-results-and-provides-business-update 2025-05-13T16:05:11-04:00 https://ir.rezolutebio.com/news/detail/354/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism 2025-05-05T08:00:13-04:00 https://ir.rezolutebio.com/news/detail/353/rezolute-to-participate-in-upcoming-investor-conferences 2025-05-01T08:00:03-04:00 https://ir.rezolutebio.com/news/detail/352/rezolute-inc-announces-closing-of-underwritten-offering 2025-04-25T16:30:36-04:00 https://ir.rezolutebio.com/news/detail/351/rezolute-announces-pricing-of-offering-of-90-million-of-common-stock-and-pre-funded-warrants 2025-04-23T08:05:01-04:00 https://ir.rezolutebio.com/news/detail/350/rezolute-announces-positive-recommendation-after-independent-interim-analysis-of-phase-3-sunrize-study-of-ersodetug-in-congenital-hyperinsulinism-hi 2025-04-23T08:00:13-04:00 https://ir.rezolutebio.com/news/detail/349/rezolute-announces-appointment-of-rare-disease-commercial-leader-erik-harris-to-its-board-of-directors 2025-03-26T07:30:01-04:00 https://ir.rezolutebio.com/news/detail/348/rezolute-reports-second-quarter-fiscal-2025-financial-results-and-provides-business-update 2025-02-12T16:05:21-05:00 https://ir.rezolutebio.com/news/detail/347/rezolute-provides-update-on-its-phase-3-sunrize-study-of-ersodetug-for-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-02-04T08:00:46-05:00 https://ir.rezolutebio.com/news/detail/346/rezolute-to-participate-in-the-guggenheim-smid-cap-biotech-conference 2025-01-31T08:00:02-05:00 https://ir.rezolutebio.com/news/detail/345/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-01-07T08:00:36-05:00 https://ir.rezolutebio.com/news/detail/344/rezolute-reports-inducement-award-under-nasdaq-listing-rule-5635c4 2024-12-05T08:00:20-05:00 https://ir.rezolutebio.com/news/detail/343/fda-grants-orphan-drug-designation-to-rezolutes-ersodetug-rz358-for-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism 2024-12-03T08:00:05-05:00 https://ir.rezolutebio.com/news/detail/342/rezolute-reports-first-quarter-fiscal-2025-financial-results-and-provides-business-update 2024-11-07T16:11:21-05:00 https://ir.rezolutebio.com/news/detail/341/rezolute-to-participate-in-upcoming-investor-conferences 2024-11-05T08:00:14-05:00 https://ir.rezolutebio.com/news/detail/340/rezolute-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-and-provides-business-update 2024-09-19T16:05:04-04:00 https://ir.rezolutebio.com/news/detail/339/fda-lifts-partial-clinical-holds-on-rz358-for-the-treatment-of-congenital-hyperinsulinism-and-authorizes-u-s-inclusion-in-ongoing-phase-3-study 2024-09-09T07:30:02-04:00 https://ir.rezolutebio.com/news/detail/338/rezolute-to-participate-in-upcoming-investor-conferences 2024-08-27T08:00:06-04:00 https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism 2024-08-05T07:30:01-04:00 https://ir.rezolutebio.com/news/detail/336/rezolute-to-participate-in-the-btig-virtual-biotechnology-conference 2024-07-31T08:00:06-04:00 https://ir.rezolutebio.com/news/detail/335/rezolute-announces-exercise-of-underwriters-option-to-purchase-additional-shares-and-concurrent-private-placement 2024-06-27T08:00:04-04:00 https://ir.rezolutebio.com/news/detail/334/rezolute-announces-closing-of-public-offering-with-approximately-60m-in-gross-proceeds 2024-06-24T08:00:09-04:00 https://ir.rezolutebio.com/news/detail/333/rezolute-announces-pricing-of-public-offering-of-60-million-of-common-stock-and-pre-funded-warrants 2024-06-13T23:30:01-04:00 https://ir.rezolutebio.com/news/detail/332/rezolute-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2024-06-13T16:01:02-04:00 https://ir.rezolutebio.com/news/detail/331/rezolute-to-participate-in-the-jefferies-global-healthcare-conference 2024-05-30T08:00:13-04:00 https://ir.rezolutebio.com/news/detail/330/rezolute-reports-positive-topline-results-from-phase-2-proof-of-concept-study-of-rz402-in-patients-with-diabetic-macular-edema-dme 2024-05-21T16:05:02-04:00 https://ir.rezolutebio.com/news/detail/329/rezolute-reports-third-quarter-fiscal-2024-financial-results-and-provides-business-update 2024-05-15T16:18:17-04:00 https://ir.rezolutebio.com/news/detail/328/phase-2-rize-study-sub-analyses-to-be-presented-at-the-2024-pediatric-endocrine-society-annual-meeting 2024-04-23T08:00:01-04:00 https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth 2024-03-06T07:30:03-05:00 https://ir.rezolutebio.com/news/detail/326/rezolute-reports-second-quarter-fiscal-2024-results-and-provides-business-update 2024-02-13T16:43:03-05:00 https://ir.rezolutebio.com/news/detail/325/rezolute-expands-leadership-team-with-appointment-of-daron-evans-ms-mba-as-chief-financial-officer 2024-01-24T08:00:05-05:00 https://ir.rezolutebio.com/news/detail/324/rezolute-receives-innovation-passport-designation-from-the-u-k-innovative-licensing-and-access-pathway-steering-group-for-rz358-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2024-01-23T08:00:04-05:00 https://ir.rezolutebio.com/news/detail/323/rezolute-initiates-phase-3-clinical-study-for-rz358-in-congenital-hyperinsulinism 2023-12-14T08:00:02-05:00 https://ir.rezolutebio.com/news/detail/322/rezolute-completes-enrollment-of-its-phase-2-study-in-diabetic-macular-edema-dme 2023-12-13T08:00:05-05:00 https://ir.rezolutebio.com/news/detail/321/rezolute-to-participate-in-btigs-3rd-annual-ophthalmology-day 2023-11-17T08:00:01-05:00 https://ir.rezolutebio.com/news/detail/320/rezolute-reports-first-quarter-fiscal-2024-results 2023-11-13T16:15:01-05:00 https://ir.rezolutebio.com/news/detail/319/rezolute-receives-priority-medicines-prime-eligibility-from-european-medicines-agency-for-enhanced-regulatory-support-of-rz358-in-congenital-hyperinsulinism 2023-10-17T08:00:03-04:00 https://ir.rezolutebio.com/news/detail/318/rezolute-announces-further-evidence-of-rz358s-efficacy-in-tumor-mediated-hyperinsulinism 2023-10-11T08:00:05-04:00 https://ir.rezolutebio.com/news/detail/317/rezolute-reports-full-year-fiscal-2023-results-and-highlights-company-progress 2023-09-14T16:08:47-04:00 https://ir.rezolutebio.com/news/detail/316/rezolute-to-participate-in-upcoming-investor-conferences-in-september 2023-09-06T07:00:05-04:00 https://ir.rezolutebio.com/news/detail/315/rezolute-to-initiate-a-pivotal-phase-3-study-of-rz358-in-participants-3-months-of-age-and-older-with-congenital-hyperinsulinism 2023-06-27T16:05:01-04:00 https://ir.rezolutebio.com/news/detail/314/rezolute-reports-third-quarter-fiscal-2023-results-and-highlights-company-progress 2023-05-11T16:17:35-04:00 https://ir.rezolutebio.com/news/detail/313/rezolute-kol-event-highlights-significant-unmet-medical-need-in-diabetic-macular-edema 2023-03-23T16:50:10-04:00 https://ir.rezolutebio.com/news/detail/312/rezolute-to-highlight-rz402-phase-2-clinical-program-with-leading-clinical-expert 2023-03-08T07:00:10-05:00 https://ir.rezolutebio.com/news/detail/311/rezolute-reports-second-quarter-fiscal-2023-results-and-highlights-company-progress 2023-02-13T09:28:11-05:00 https://ir.rezolutebio.com/news/detail/310/rezolute-announces-initiation-of-a-phase-2-study-of-rz402-in-patients-with-diabetic-macular-edema 2022-12-15T07:00:05-05:00 https://ir.rezolutebio.com/news/detail/309/rezolute-reports-first-quarter-fiscal-2023-results-and-highlights-company-progress 2022-11-09T16:43:33-05:00 https://ir.rezolutebio.com/news/detail/308/rezolute-to-present-at-the-jefferies-london-healthcare-conference 2022-11-01T07:00:05-04:00 https://ir.rezolutebio.com/news/detail/307/rezolute-announces-presentation-at-the-retina-society-55th-annual-scientific-meeting 2022-10-20T07:00:15-04:00 https://ir.rezolutebio.com/news/detail/306/rezolute-reports-fourth-quarter-and-full-year-fiscal-2022-results-and-highlights-company-progress 2022-09-15T17:00:29-04:00 https://ir.rezolutebio.com/news/detail/305/rezolute-announces-presentation-at-the-60th-annual-espe-meeting 2022-09-07T07:00:11-04:00 https://ir.rezolutebio.com/news/detail/304/rezolute-announces-promotion-of-brian-roberts-m-d-to-chief-medical-officer 2022-06-01T07:00:07-04:00 https://ir.rezolutebio.com/news/detail/303/rezolute-reports-third-quarter-fiscal-2022-financial-results-and-highlights-company-progress 2022-11-09T16:43:41-05:00 https://ir.rezolutebio.com/news/detail/302/rezolute-to-host-corporate-update-call-on-may-4-2022 2022-05-04T16:01:02-04:00 https://ir.rezolutebio.com/news/detail/301/rezolute-inc-announces-closing-of-registered-direct-offering 2022-05-04T09:33:13-04:00 https://ir.rezolutebio.com/news/detail/300/rezolute-inc-announces-aggregate-130-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market 2022-05-01T23:25:15-04:00 https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism 2022-05-01T14:00:02-04:00 https://ir.rezolutebio.com/news/detail/298/rz358-phase-2b-rize-study-topline-data-to-be-unveiled-at-pediatric-endocrine-society-annual-meeting-on-may-1-2022 2022-04-26T16:05:11-04:00 https://ir.rezolutebio.com/news/detail/297/rezolute-joins-the-rare-disease-company-coalition 2022-03-29T07:00:02-04:00 https://ir.rezolutebio.com/news/detail/296/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hyperinsulinism 2022-03-23T07:00:01-04:00 https://ir.rezolutebio.com/news/detail/295/rezolute-announces-positive-study-results-for-rz402-an-oral-pki-being-developed-for-dme 2022-02-22T07:00:04-05:00 https://ir.rezolutebio.com/news/detail/294/rezolute-reports-second-quarter-fiscal-2022-financial-results-and-highlights-company-progress 2022-02-09T16:05:02-05:00 https://ir.rezolutebio.com/news/detail/293/rezolute-reports-first-quarter-fiscal-2022-financial-results-and-highlights-recent-company-progress 2021-11-12T16:05:03-05:00 https://ir.rezolutebio.com/news/detail/292/rezolute-announces-pricing-of-public-offering-of-55-million-of-common-stock-and-pre-funded-warrants-and-concurrent-registered-direct-offering 2021-10-13T08:10:41-04:00 https://ir.rezolutebio.com/news/detail/291/rezolute-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-and-a-concurrent-registered-direct-offering 2021-10-12T16:05:04-04:00 https://ir.rezolutebio.com/news/detail/290/rezolute-presents-results-from-two-week-natural-history-study-in-congenital-hyperinsulinism-patients-on-standard-of-care-therapies-at-espe-2021 2021-09-22T16:05:06-04:00 https://ir.rezolutebio.com/news/detail/289/rezolute-reports-fourth-quarter-and-full-year-fiscal-2021-financial-results-and-highlights-recent-company-progress 2021-09-15T16:56:24-04:00 https://ir.rezolutebio.com/news/detail/288/rezolute-announces-initiation-of-dosing-in-the-second-cohort-of-its-phase-2b-trial-of-rz358-for-congenital-hyperinsulinism 2021-09-09T16:05:04-04:00 https://ir.rezolutebio.com/news/detail/287/rezolute-to-participate-in-upcoming-virtual-healthcare-conferences 2021-09-07T16:05:08-04:00 https://ir.rezolutebio.com/news/detail/286/rezolute-announces-initiation-of-multiple-ascending-dose-study-of-rz402rezolutes-oral-pki-for-treatment-of-dme 2021-08-10T07:00:03-04:00 https://ir.rezolutebio.com/news/detail/285/rezolute-to-participate-in-upcoming-virtual-healthcare-conferences 2021-08-03T07:00:02-04:00 https://ir.rezolutebio.com/news/detail/284/rezolute-added-to-russell-microcap-index 2021-06-28T07:00:04-04:00 https://ir.rezolutebio.com/news/detail/283/rezolute-to-participate-in-upcoming-virtual-healthcare-conferences 2021-06-11T16:08:51-04:00 https://ir.rezolutebio.com/news/detail/282/rezolute-expands-leadership-team-with-the-appointment-of-davelyn-hood-md-as-director-scientific-and-patient-affairs 2021-05-20T07:00:02-04:00 https://ir.rezolutebio.com/news/detail/281/rezolute-appoints-leading-ophthalmology-expert-quan-dong-nguyen-md-msc-faao-farvo-to-scientific-advisory-board 2021-05-18T07:00:03-04:00 https://ir.rezolutebio.com/news/detail/280/rezolute-reports-third-quarter-fiscal-2021-financial-results-and-highlights-recent-company-progress 2021-05-17T16:05:17-04:00 https://ir.rezolutebio.com/news/detail/279/rezolute-to-present-at-the-oppenheimer-rare-and-orphan-disease-summit 2021-05-17T07:00:02-04:00 https://ir.rezolutebio.com/news/detail/278/rezolute-announces-positive-rz402-study-results-demonstrating-potential-for-once-daily-dosing-of-an-oral-plasma-kallikrein-inhibitor-for-diabetic-macular-edema 2021-05-04T08:00:13-04:00 https://ir.rezolutebio.com/news/detail/277/rezolute-announces-30-million-debt-financing-agreement-with-slr-capital-partners 2021-04-19T08:00:05-04:00 https://ir.rezolutebio.com/news/detail/276/rezolute-presents-data-on-rz358-in-post-gastric-bypass-hypoglycemia-at-endo-2021 2021-03-22T08:00:01-04:00 https://ir.rezolutebio.com/news/detail/275/rezolute-strengthens-board-of-directors-with-key-appointments-of-leading-rare-disease-experts 2021-03-08T08:00:04-05:00 https://ir.rezolutebio.com/news/detail/274/rezolute-to-participate-in-upcoming-investor-conferences-in-march 2021-03-02T17:16:51-05:00 https://ir.rezolutebio.com/news/detail/273/rezolute-reports-second-quarter-fiscal-2021-financial-results 2021-02-10T16:05:01-05:00 https://ir.rezolutebio.com/news/detail/272/rezolute-announces-initiation-of-phase-1-study-of-rz402-an-oral-plasma-kallikrein-inhibitor-for-the-treatment-of-diabetic-macular-edema 2021-01-12T08:30:02-05:00 https://ir.rezolutebio.com/news/detail/271/rezolute-announces-change-of-transfer-agent 2020-12-28T16:05:00-05:00 https://ir.rezolutebio.com/news/detail/270/fda-clears-rezolutes-ind-application-for-rz402 2020-12-03T08:00:01-05:00 https://ir.rezolutebio.com/news/detail/269/rezolute-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference 2020-11-19T08:00:14-05:00 https://ir.rezolutebio.com/news/detail/268/rezolute-announces-uplisting-to-the-nasdaq-capital-market 2020-11-06T11:16:59-05:00 https://ir.rezolutebio.com/news/detail/267/rezolute-announces-41-million-private-placement-with-leading-investment-firms-and-prepares-to-imminently-up-list-to-nasdaq 2020-10-09T08:30:05-04:00 https://ir.rezolutebio.com/news/detail/266/rezolute-inc-welcomes-pharmaceutical-industry-leader-philippe-fauchet-to-its-board-of-directors 2020-09-10T08:00:14-04:00 https://ir.rezolutebio.com/news/detail/265/rezolute-inc-provides-updates-in-the-context-of-the-covid-19-pandemic-announces-resumption-and-us-expansion-of-its-phase-2b-study-in-congenital-hyperinsulinism 2020-07-27T08:00:13-04:00 https://ir.rezolutebio.com/news/detail/264/rezolute-announces-publication-of-rz402-data-in-diabetic-macular-edema-dme-in-investigative-ophthalmology-visual-science 2020-06-15T08:30:09-04:00 https://ir.rezolutebio.com/news/detail/263/rezolute-receives-rare-pediatric-disease-designation-for-rz358-phase-2b-candidate-for-the-treatment-of-congenital-hyperinsulinism-enabling-eligibility-for-priority-review-voucher 2020-06-10T08:30:09-04:00 https://ir.rezolutebio.com/news/detail/262/rezolute-presents-rz358-clinical-data-validated-model-of-the-pharmacokinetics-and-glycemic-response-in-congenital-hyperinsulinism-at-pediatric-endocrine-society-2020-annual-meeting 2020-06-01T08:30:08-04:00 https://ir.rezolutebio.com/news/detail/261/rezolute-to-present-clinical-data-for-rz358-lead-candidate-in-phase-2b-trial-in-congenital-hyperinsulinism-at-virtual-pediatric-endocrine-society-2020-annual-meeting 2020-05-28T08:30:06-04:00 https://ir.rezolutebio.com/news/detail/260/rezolute-inc-announces-updates-to-clinical-and-business-operations-in-response-to-covid-19-pandemic 2020-05-14T16:15:09-04:00 https://ir.rezolutebio.com/news/detail/259/rezolute-initiates-phase-2b-clinical-trial-of-lead-candidate-rz358-in-congenital-hyperinsulinism 2020-02-10T08:30:13-05:00 https://ir.rezolutebio.com/news/detail/258/rezolute-to-present-at-bio-ceo-investor-conference-2020 2020-01-27T08:30:08-05:00 https://ir.rezolutebio.com/news/detail/257/rezolute-inc-announces-top-line-results-from-phase-1-trial-evaluating-ab101-in-patients-with-diabetes 2019-12-18T15:00:05-05:00 https://ir.rezolutebio.com/news/detail/256/rezolute-management-to-present-at-2020-biotech-showcase-conference 2019-12-02T09:25:03-05:00 https://ir.rezolutebio.com/news/detail/255/rezolute-appoints-nektar-therapeutics-coo-cfo-to-its-board-of-directors 2019-11-25T09:25:03-05:00 https://ir.rezolutebio.com/news/detail/254/rezolute-management-to-present-at-2019-bio-investor-forum-conference 2019-11-18T22:20:00-05:00 https://ir.rezolutebio.com/news/detail/253/rezolute-management-to-present-at-2019-canaccord-genuity-growth-conference 2019-11-18T22:20:41-05:00 https://ir.rezolutebio.com/news/detail/252/rezolute-completes-45-million-investment-round-with-full-exercise-of-20-million-option 2019-11-18T22:21:24-05:00 https://ir.rezolutebio.com/news/detail/251/rezolute-announces-25-million-private-placement----potential-total-investment-of-45-million 2019-01-07T08:39:40-05:00 https://ir.rezolutebio.com/news/detail/250/rezolute-announces-appointment-of-keith-vendola-as-chief-financial-officer 2018-05-16T08:00:04-04:00 https://ir.rezolutebio.com/news/detail/249/rezolute-announces-appointment-of-congenital-hyperinsulinism-therapeutic-area-expert-dr-christine-ferrara-as-director-of-clinical-development 2018-04-09T08:00:14-04:00 https://ir.rezolutebio.com/news/detail/248/rezolute-announces-appointment-of-hoyoung-huh-m-d-ph-d-as-vice-chairman-of-its-board-of-directors 2018-04-04T08:00:11-04:00 https://ir.rezolutebio.com/news/detail/247/rezolute-inc-announces-close-of-convertible-note-financing 2018-04-03T13:26:01-04:00 https://ir.rezolutebio.com/news/detail/246/update---rezolute-inc-enters-into-common-stock-purchase-agreement-for-up-to-10-million-with-lincoln-park-capital-fund-llc 2017-12-26T11:40:54-05:00 https://ir.rezolutebio.com/news/detail/245/antriabio-announces-exclusive-license-agreement-for-a-phase-2-orphan-disease-therapy-with-xoma-corporation-and-name-change-to-rezolute-inc 2017-12-07T08:30:09-05:00 https://ir.rezolutebio.com/news/detail/244/antriabio-announces-selection-of-lead-oral-plasma-kallikrein-inhibitor-candidates-for-the-treatment-of-diabetic-retinopathy-diabetic-macular-edema-and-hereditary-angioedema 2017-10-19T11:55:06-04:00 https://ir.rezolutebio.com/news/detail/243/antriabio-appoints-nektar-therapeutics-cfo-to-its-board-of-directors 2017-10-09T08:00:06-04:00 https://ir.rezolutebio.com/news/detail/242/antriabio-appoints-dr-robert-bhisitkul-to-its-scientific-advisory-board 2017-10-04T08:00:06-04:00 https://ir.rezolutebio.com/news/detail/241/antriabio-and-activesite-pharmaceuticals-announce-license-and-development-agreement-for-plasma-kallikrein-inhibitors 2017-08-07T08:00:09-04:00 https://ir.rezolutebio.com/news/detail/240/antriabio-announces-first-patient-dosed-in-phase-1-clinical-study-of-ab101 2017-07-25T08:00:02-04:00 https://ir.rezolutebio.com/news/detail/239/antriabio-announces-13-million-close-of-private-placement-transaction-and-plan-to-dose-first-patient-with-ab101-this-month 2017-07-17T08:00:01-04:00 https://ir.rezolutebio.com/news/detail/238/antriabio-files-investigational-new-drug-application-for-once-weekly-basal-insulin-ab101 2017-06-05T08:00:10-04:00 https://ir.rezolutebio.com/news/detail/237/antriabio-formally-engages-cro-for-the-conduct-of-its-phase-i-first-in-human-clinical-trial-of-ab101 2017-05-01T08:00:01-04:00 https://ir.rezolutebio.com/news/detail/236/antriabio-appoints-two-pharmaceutical-executives-to-its-board-of-directors 2017-03-22T08:00:04-04:00 https://ir.rezolutebio.com/news/detail/235/antriabio-announces-offer-to-amend-warrants-to-purchase-shares-of-common-stock 2016-12-15T17:15:00-05:00 https://ir.rezolutebio.com/news/detail/234/antriabio-announces-formation-of-subsidiary-and-plan-to-raise-capital-in-south-korea 2016-09-22T08:00:01-04:00 https://ir.rezolutebio.com/news/detail/233/antriabio-announces-12-million-private-placement 2016-06-29T08:00:00-04:00 https://ir.rezolutebio.com/news/detail/232/antriabio-announces-preclinical-proof-of-concept-for-once-weekly-basal-insulin-ab101-in-diabetic-miniature-swine 2016-06-22T08:00:07-04:00 https://ir.rezolutebio.com/news/detail/231/antriabio-announces-appointment-of-michael-deperro-as-vice-president-of-operations 2016-01-06T08:30:01-05:00 https://ir.rezolutebio.com/news/detail/230/antriabio-announces-first-close-of-private-placement-transaction 2015-12-10T12:50:21-05:00 https://ir.rezolutebio.com/news/detail/229/antriabio-receives-notice-of-allowance-on-patent-covering-microsphere-drug-delivery-platform 2015-11-17T08:30:02-05:00 https://ir.rezolutebio.com/news/detail/228/antriabio-announces-new-product-candidate-ab301-a-weekly-glp-1-agonist-and-basal-insulin-combination-for-type-2-diabetes 2015-09-16T07:30:01-04:00 https://ir.rezolutebio.com/news/detail/227/antriabio-appoints-david-f-welch-ph-d-to-its-board-of-directors 2015-06-29T08:00:04-04:00 https://ir.rezolutebio.com/news/detail/226/antriabio-announces-promising-preclinical-results-for-once-weekly-basal-insulin-ab101 2015-06-08T07:30:00-04:00 https://ir.rezolutebio.com/news/detail/225/antriabio-to-present-new-preclinical-data-at-the-american-diabetes-association-75th-scientific-sessions 2015-05-11T08:00:00-04:00 https://ir.rezolutebio.com/news/detail/224/antriabio-announces-appointment-of-dr-hoyoung-huh-as-chairman-of-scientific-advisory-board-and-business-development 2015-01-08T07:35:00-05:00 https://ir.rezolutebio.com/news/detail/214/antriabio-announces-completion-of-pkpd-studies-of-ab101-in-two-species 2015-01-07T08:00:00-05:00 https://ir.rezolutebio.com/news/detail/204/antriabio-announces-7-million-private-placement 2015-01-05T07:36:43-05:00 https://ir.rezolutebio.com/news/detail/194/antriabio-extinguishes-44-million-contingent-liability 2014-11-10T14:45:56-05:00 https://ir.rezolutebio.com/news/detail/184/antriabio-appoints-barry-sherman-m-d-to-its-board-of-directors 2014-07-23T07:35:00-04:00 https://ir.rezolutebio.com/news/detail/174/antriabio-appoints-c-ronald-kahn-m-d-to-its-scientific-advisory-board 2014-06-23T07:35:00-04:00 https://ir.rezolutebio.com/news/detail/164/antriabio-inc-to-present-at-the-third-annual-marcum-microcap-conference-on-thursday-may-29-2014 2014-05-22T15:29:04-04:00 https://ir.rezolutebio.com/news/detail/154/antriabio-inc-establishes-manufacturing-and-laboratory-facility-in-colorado 2014-05-12T07:35:00-04:00 https://ir.rezolutebio.com/news/detail/144/antriabio-inc-announces-1-for-6-reverse-stock-split 2014-05-01T12:02:58-04:00 https://ir.rezolutebio.com/news/detail/134/antriabio-inc-launches-digital-corporate-communication-channels 2017-10-20T15:09:22-04:00 https://ir.rezolutebio.com/news/detail/124/antriabio-announces-formation-of-scientific-advisory-board 2014-04-23T08:15:07-04:00 https://ir.rezolutebio.com/news/detail/114/antriabio-inc-announces-10-million-private-placement 2014-04-02T07:36:45-04:00 https://ir.rezolutebio.com/news/detail/104/antriabio-inc-to-present-at-26th-annual-roth-conference 2014-03-06T08:05:00-05:00 https://ir.rezolutebio.com/news/detail/94/antriabio-to-present-at-16th-annual-bio-ceo-investor-conference-on-tuesday-february-11-2014 2014-02-05T08:05:05-05:00 https://ir.rezolutebio.com/news/detail/84/antriabio-announces-closing-of-bridge-financing 2014-01-16T10:06:39-05:00 https://ir.rezolutebio.com/news/detail/74/antriabio-granted-european-patent-allowance-for-method-of-preparing-site-specific-protein-conjugates 2013-07-24T08:30:00-04:00 https://ir.rezolutebio.com/news/detail/64/antriabio-initiates-effort-to-raise-up-to-12-million-in-a-private-placement 2013-07-01T08:30:03-04:00 https://ir.rezolutebio.com/news/detail/63/antriabio-appoints-two-industry-leaders-to-its-management-team 2013-02-19T10:38:08-05:00 https://ir.rezolutebio.com/news/detail/53/antriabio-announces-stock-ticker-symbol-change-to-antb 2013-02-08T10:45:25-05:00 https://ir.rezolutebio.com/news/detail/43/update-antriabio-completes-merger-and-elects-board-of-directors 2013-02-06T13:11:20-05:00 https://ir.rezolutebio.com/news/detail/33/antriabio-acquires-assets-of-pr-pharmaceuticals-and-announces-intent-to-merge-with-a-public-company 2013-01-07T09:30:54-05:00 https://ir.rezolutebio.com/events/detail/20251211-sunrize-topline-data-conference-call 2025-12-11T07:19:47-05:00 https://ir.rezolutebio.com/events/detail/20251119-2026-annual-meeting-of-stockholders 2025-10-07T16:20:59-04:00 https://ir.rezolutebio.com/events/detail/20251110-rezolute-investor-event 2025-11-10T13:42:50-05:00 https://ir.rezolutebio.com/sec-filings/content/0000912282-26-000533/form4.html 2026-03-31T17:00:15-04:00 https://ir.rezolutebio.com/sec-filings/content/0000102909-26-000401/primary_doc.html 2026-03-26T11:08:07-04:00 https://ir.rezolutebio.com/sec-filings/content/0001104659-26-033592/tm269642d1_8k.htm 2026-03-24T07:30:48-04:00 https://ir.rezolutebio.com/sec-filings/content/0000912282-26-000412/form4.html 2026-03-04T18:18:22-05:00 https://ir.rezolutebio.com/sec-filings/content/0000912282-26-000411/form4.html 2026-03-04T18:17:04-05:00 https://ir.rezolutebio.com/sec-filings/content/0000912282-26-000410/form4.html 2026-03-04T18:08:05-05:00 https://ir.rezolutebio.com/sec-filings/content/0002005369-26-000010/primary_doc.html 2026-02-13T11:40:37-05:00 https://ir.rezolutebio.com/sec-filings/content/0001104659-26-014334/rzlt-20251231x10q.htm 2026-02-12T16:38:58-05:00 https://ir.rezolutebio.com/sec-filings/content/0001104659-26-014287/tm265567d1_8k.htm 2026-02-12T16:13:57-05:00 https://ir.rezolutebio.com/sec-filings/content/0000070858-26-000071/primary_doc.html 2026-02-11T14:02:29-05:00 https://ir.rezolutebio.com/privacy-policy https://ir.rezolutebio.com/disclaimer https://ir.rezolutebio.com/sitemap